



21 April 2021

Opyl completes oversubscribed share purchase plan

Tuesday 21 April 2021, Opyl Limited (ASX:OPL) ("Opyl" or the "Company") is pleased to announce it has now successfully completed its Share Purchase Plan (**SPP**) that closed on Friday 16 April 2021 raising \$1.3M, after scaling back total applications by around 50%.

The SPP received overwhelming support and was heavily oversubscribed with over \$2.6M in applications. The board wishes to thank shareholders for their support and this endorsement of the Company's strategy.

The scale-back took into account both shareholding levels at the SPP record date and also the quantum of individual applications received. The Board considered this the more equitable method of scale-back. The company was able to accept a higher amount from the SPP, however with the growth trajectory, the \$1.3M from the recent placement and \$1.3M from the SPP provides sufficient capital for the company to execute on its growth plans over the coming 24 months.

Combined with the recent placement, Opyl is now in a strong financial position after raising over \$2.65M. The company remains focused on completing development and rolling out its market insights and clinical trial platforms.

Excess application monies as a result of the scale-back will be refunded to applicants without interest in accordance with the SPP booklet and will be processed by the Company's registry as soon as practicable after the allotment of the SPP shares.

The 8,666,738 new shares will be issued on Monday, 26 April 2021. These shares are expected to commence trading on ASX on Monday 26 April 2021. New shares issued under the SPP will rank equally with existing OPL ordinary shares from their date of issues.

Holding statements are expected to be dispatched on or around Tuesday 27 April 2021.

The Board and management once again thanks its shareholders for their strong support of the Company and SPP.

The Board has authorised this announcement for release to the ASX.

-ENDS-

For media enquiries: Laura Blue +61 416 699 925

For investor enquiries: info@opyl.ai

www.opyl.ai

Opyl is a new generation Australian company that provides leading biopharma and health organisations access to emerging AI-assisted technologies and real-world data insights to understand and improve healthcare design, development, and delivery.

Opyl works at the intersection of clinical trials, artificial intelligence, and social media.

Our key offering for biopharma, medtech, government and healthcare organisations:

- clinical trial recruitment and retention solutions
- clinical trial predictive analytics
- deep social media insights



Our vision is to improve health and wellness by optimising data assets and digital activation to advance technologies for life.

Follow Opyl on Twitter (@Opylai), LinkedIn and Facebook